Beactica Therapeutics advances novel LSD1-CoREST degrader for glioblastoma into IND-enabling phase
Executive summary: Beactica Therapeutics AB started IND-enabling studies for BEA-17, an oral first-in-class degrader of LSD1 and CoREST intended for glioblastoma treatment. Successful completion of these studies is a prerequisite for human clinical trials, representing a major de-risking step for the company's lead asset in a high-unmet-need oncology market.
Who is involved: Beactica Therapeutics AB (Swedish precision medicine company).
Likely next: Completion of toxicology and pharmacology data collection to support a formal IND filing with regulatory authorities.
Beactica Therapeutics has officially commenced the preclinical stage required to file an Investigational New Drug (IND) application for its lead compound, BEA-17. This oral degrader specifically targets the LSD1 and CoREST epigenetic regulators, positioning it as a first-in-class therapeutic for glioblastoma. The transition to IND-enabling studies marks a critical milestone in moving from discovery to clinical regulatory submission.
What's next — scenarios
Base: Successful IND filing (60%)
Beactica transitions to Phase I clinical trials, likely increasing company valuation and attractiveness for partnerships.
- Completion of toxicology studies without significant safety signals
Upside: Early licensing deal (25%)
A large pharmaceutical partner provides non-dilutive capital based on preclinical data strength.
- Positive pharmacological efficacy data in glioblastoma models
Downside: Preclinical safety failure (15%)
Development of BEA-17 is halted or delayed, requiring a pivot to different compounds or targets.
- Unfavorable toxicity profiles in IND-enabling animal models
What to watch
- Completion of preclinical toxicology data packages
- Official announcement of IND submission to regulatory bodies
Timeline
- — Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma (PR Newswire)
Analysis — what this means
Likely next events
- Submission of IND application following study completion
Sectors affected
- Oncology therapeutics
- Epigenetic drug development
- Precision medicine
Regulatory implications
- Requirement of IND-enabling data to meet FDA/EMA standards for human testing